Detailed Information
Cited 26 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI).
- Authors
- Park, Keunchil; Lee, Jong-Seok; Lee, Ki Hyeong; Kim, Joo-Hang; Min, Young Joo; Cho, Jae Yong; Han, Ji-Youn; Kim, Bong-Seog; Kim, Jin-Soo; Lee, Dae Ho; Kang, Jin Hyoung; Cho, Eun Kyung; Jang, In-Jin; Jung, Jina; Kim, Hyo-Yeon; Sin, Hui Jung; Son, Jeewoong; Woo, Jong Soo; Kim, Dong-Wan
- Issue Date
- 20-May-2015
- Publisher
- AMER SOC CLINICAL ONCOLOGY
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.33, no.15
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 33
- Number
- 15
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Related Researcher
- Cho, Eun Kyung
- College of Medicine (Department of Medicine)